Efficacy of 153Sm-EDTMP in the treatment of prostate cancer with bone metastasis
Feng, J.-Y.; Wu, C.-Q.; Zhang, P.; Wang, S.-J.; Zheng, X.-H.
Zhonghua Nan Ke Xue 18(11): 982-985
2012
ISSN/ISBN: 1009-3591 PMID: 23214246 Document Number: 661287
To investigate the efficacy of 153Sm-EDTMP in the treatment of bone metastasis of prostate cancer (PCa) by comparison with zoledronic acid. We assigned 55 PCa patients with bone metastasis to receive 153Sm-EDTMP (n = 31) and zoledronic acid (n = 24), the former injected intravenously at the dose of 37.0 MBq/kg body weight, and the latter administered by slow intravenous drip at 4 mg in 100 ml of 0.9% sodium chloride. We performed 99mTc-MDP bone scan before and 1 -2 months after the treatment. The rate of pain relief was 83.9% in the 153Sm-EDTMP group and 58.3% in the zoledronic acid group (P = 0.035), and that of bone metabolism change was 64.5% in the former and 33.3% in the latter (P = 0.022). 153Sm-EDTMP is an ideal agent for the treatment of prostate cancer with bone metastasis.